Abstract
Adoptive immunotherapy is a promising approach in the treatment of multiple myeloma. We have tested the identification, separation, and expansion of allogeneic myeloma-specific T cells in vitro. Irradiated myeloma cell line ARH 77 has been used to stimulate allogeneic CD4+ and CD8+ T lymphocytes. Activated myeloma-specific T cells that produced interferon-gamma were isolated using immunomagnetic beads and further expanded in vitro to numbers of up to 400×106 T cells. Specificity of the T lymphocytes was tested using a 5-(6-)carboxyfluoresceine diacetate succinimidyl ester (CFSE)—based cytotoxicity test. This study demonstrates the feasibility of identification and isolation of tumor-specific T cells from allogeneic donors that can be expanded in vitro to numbers useful for clinical applications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barlogie B, et al. Treatment of multiple myeloma. Blood 2004, 1: 20–32.
Attal M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.
Bakkus MH, et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004; 126: 665–674.
Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bargenbrant S. Idlotype immunization combined with GM-CSF in myeloma patiens induced type I, MHC restricted, CD4-and CD8-specific T-cell responses. Blood 1998; 91: 2458–2466.
Massaia M et al. Idiotype vaccination in human myeloma:generation of tumor-specific immune response after high-dose chemotherapy. Blood 1999; 94: 673–683.
Wen YJ, Barlogie B, Yi Q, Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97: 1750–1755.
Buchler T, Hajek R Dendritic cell vaccines in the treatment of multiple myeloma. Med Oncol 2002; 19: 213–218.
Yi Q. Immunoregulatory mechanisms and immunotherapy In Mehta J, Singhal S (eds), Myeloma Martin Dunitz: London, 2002, pp. 81–97.
Brown RD, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-betal and interleukin-10. Blood 2001; 93: 2992–2998.
Cook G, Campbell JDM. Immune regulation in multiple myeloma: the host-tumor conflict. Blood Rev 1999; 13: 151–162.
Hayashi T, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435–1442.
Hajek R, Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol 2000; 17: 2–15.
Očadlíková D, et al., Identification of tumor-specific T cells based on interferon gamma production in multiple myeloma. Klin onkol (in Czech, abstract in English) 2005: 18: 55–58.
Brosterhus H, et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cylokiae secretion. Eur J Immunol 1999; 29: 4053–4059.
Becker C, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7: 1159–1162.
Kroger N, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002: 100: 3919–3924.
Lee CK, et al. Prognostic factors in allogeneic transplantation for patients with high risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73–80.
Michalek J, et al. Definitive separation of graft-versus-leukemia-and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 2003; 100: 1180–1184.
Michalek J, Collins RH, Vitetta ES. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. Neoplasma 2003; 50: 296–269
Solomon SR, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005: 106: 1123–1129.
Marin L, et al. Flow cytometric quantifitation of apoptosis and proliferation in mixe lymphocyte culture. Cytometry A 2003; 51: 107–118.
Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon D. A novel technique for the fluorometric assesment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249: 219–220.
Jedema I, van der Werff N, Barge RMY, Willemze R, Falkenburg JHF, A new CFSE based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor sells within a heterogenous target cell popuation. Blood 2004; 103: 2677–2682.
Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dyedilution. J Immunol Methods 2000; 243: 147–154.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ocadlikova, D., Zahradova, L., Kovarova, L. et al. Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy. Med Oncol 23, 377–384 (2006). https://doi.org/10.1385/MO:23:3:377
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MO:23:3:377